Compare Merck & Co., Inc. (MRK) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NetEase Inc — how do they compare? Merck & Co., Inc. trades at $142.17 (market cap $351.28B), while NetEase Inc trades at $123.03 (market cap $76.09B). The key difference: Merck & Co., Inc. is far larger — about 4.6× NetEase Inc's market cap, and NetEase Inc pays the higher dividend (2.45%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and NetEase Inc for 74 Days on average.
| MRK | NTES | |
|---|---|---|
Market Cap | $351.28B | $76.09B |
Volume | 7,969,665 | 486,447 |
Sector | Health | Technology |
52-Week High | $156.43 | $152.85 |
52-Week Low | $82.49 | $109.26 |
Typical Hold Time | 98 Days | 74 Days |
Enterprise Value | $398.04B | $51.81B |
Dividend Yield | 2.39% | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
NetEase (NTES) trades at $120.61, up 1.29% with neutral technical signals and mixed earnings performance. The company maintains strong fundamentals with $112.63B revenue, 27.88% net margin, and robust cash flow. Recent Q2 2026 earnings missed expectations despite revenue growth, while analyst consensus remains strongly bullish with $168 price target representing 39% upside potential.
NTES presents compelling value with reasonable valuation multiples (P/E 16.06, EV/EBITDA 8.15) and strong profitability metrics. Key risks include earnings volatility and competitive pressures in gaming. The stock offers attractive upside based on analyst targets, supported by the company's solid balance sheet and consistent dividend growth track record.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
